Oasmia’s products and product candidates are based on the proprietary technology platform XR17. This allows for a nano-sized particle formulations of active pharmaceutical ingredients (“API”), which otherwise are non-soluble in water and thus, administration to patients is possible. With a combination of XR17 and an API, new innovative, patent-protectable medicines will be created. The benefits of XR17 are not restricted to cancer drugs and Oasmia is considering applying the technology to other drug classes that will benefit from solubility enhancement.
Oasmia has products and product candidates within human health as well as animal health.